NCT07241676|Enrolling By Invitation
Early Recurrence After Surgery for Pancreatic Cancer
POCEMON BLUE
Early Recurrence and Futility After Curative-intent Resection of Pancreatic Ductal Adenocarcinoma
Loading search results
POCEMON BLUE
Early Recurrence and Futility After Curative-intent Resection of Pancreatic Ductal Adenocarcinoma
Sponsor study identifier
observational
500
1 country
1
Study Start
October 23, 2025
Actual (reported)Primary Completion
September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The goal of this observational study is to learn about early recurrence after curative-intent surgery for pancreatic cancer. The main questions it aims to answer are:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 23, 2025
Actual (reported)November 17, 2025
Actual (reported)November 21, 2025
Actual (reported)September 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Incidence, timing, mode of detection, and anatomical site of early recurrence
Early recurrence (ER) is defined as disease recurrence occurring within 12 months after curative-intent resection (R0 or R1) for pancreatic ductal adenocarcinoma. The incidence, time from surgery to recurrence, mode of detection (radiologic vs biochemical), and anatomical site (liver, lung, local, peritoneum, multiple) will be prospectively assessed.
Within 12 months post-surgery
Comparison of ER patterns in patients treated with neoadjuvant therapy versus upfront surgery
12 months post-surgery
Incidence and clinical impact of biochemical-only recurrence
12 months post-surgery
Post-recurrence treatment strategies and short-term survival outcomes
From recurrence up to 24 months post-surgery
Clinical and pathological predictors of early recurrence
Up to 12 months post-surgery
Validation of futility criteria for upfront surgery patients
Within 6 months post-surgery
Adult patients with histologically confirmed PDAC who undergo curative-intent resection (R0 or R1), with no distant metastases, including both upfront and post-neoadjuvant cases.
Standard-of-care surgical resection for pancreatic ductal adenocarcinoma, as determined by the multidisciplinary team. No study-specific interventions are mandated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adult patients (≥18 years) with histologically confirmed pancreatic ductal adenocarcinoma undergoing curative-intent resection (R0 or R1) without evidence of distant metastases at the time of surgery. Both patients treated with neoadjuvant therapy and those undergoing upfront surgery are eligible.
University of Padova
Padova, PD, 35128, Italy
Giovanni Marchegiani, MD PhD
University of Padova
Giampaolo Perri, MD PhD
University of Padova
First Submitted
November 17, 2025
First Posted
November 21, 2025
Study Start
October 23, 2025
Actual (reported)Primary Completion
September 30, 2026
Estimated (date passed)A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 30, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
November 21, 2025
Record last verified: 2025-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: